• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.29% Nasdaq Down0.87%

    Geron Corporation (GERN)

    2.92 Down 0.09(2.99%) Oct 13, 4:00PM EDT
    |After Hours : 2.95 Up 0.03 (1.03%) Oct 13, 4:53PM EDT
    ProfileGet Profile for:
    Geron Corporation
    149 Commonwealth Drive
    Suite 2070
    Menlo Park, CA 94025
    United States - Map
    Phone: 650-473-7700
    Fax: 650-473-7750
    Website: http://www.geron.com

    Index Membership:N/A
    Full Time Employees:42

    Business Summary 

    Geron Corporation, a clinical stage biopharmaceutical company, focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. It has collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize imetelstat worldwide for indications in oncology, including hematologic myeloid malignancies and other human therapeutic uses. The company was founded in 1990 and is based in Menlo Park, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Geron Corporation

    Corporate Governance 
    Geron Corporation’s ISS Governance QuickScore as of Oct 1, 2015 is 6. The pillar scores are Audit: 1; Board: 3; Shareholder Rights: 7; Compensation: 5.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Dr. John A. Scarlett M.D., 64
    Chief Exec. Officer, Pres and Director
    Ms. Olivia Kyusuk Bloom , 46
    Chief Financial Officer, Exec. VP of Fin. and Treasurer
    Dr. Andrew J. Grethlein Ph.D., 51
    Exec. VP of Devel. and Technical Operations
    Mr. Stephen N. Rosenfield J.D., 65
    Exec. VP of Legal Affairs & HR, Gen. Counsel and Corp. Sec.
    Mrs. Melissa A. Kelly Behrs , 51
    Exec. VP of Bus. Devel. and Portfolio & Alliance Management
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders